TY  - GEN
AU  - Byrd,John C
AU  - Kipps,Thomas J
AU  - Flinn,Ian W
AU  - Castro,Januaro
AU  - Lin,Thomas S
AU  - Wierda,William
AU  - Heerema,Nyla
AU  - Woodworth,James
AU  - Hughes,Steve
AU  - Tangri,Shabnam
AU  - Harris,Sarah
AU  - Wynne,Dee
AU  - Molina,Arturo
AU  - Leigh,Bryan
AU  - O'Brien,Susan
TI  - Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia
SN  - 1528-0020
PY  - 2010///0223
KW  - Aged
KW  - Aged, 80 and over
KW  - Antibodies, Monoclonal
KW  - administration & dosage
KW  - Antibodies, Monoclonal, Murine-Derived
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - adverse effects
KW  - Cyclophosphamide
KW  - Disease-Free Survival
KW  - Dose-Response Relationship, Drug
KW  - Drug Resistance, Neoplasm
KW  - drug effects
KW  - Female
KW  - Humans
KW  - Leukemia, Lymphocytic, Chronic, B-Cell
KW  - blood
KW  - Male
KW  - Middle Aged
KW  - Recurrence
KW  - Rituximab
KW  - Vidarabine
N1  - Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1182/blood-2009-08-237727
ER  -